A Randomized, Prospective, Double-blind, Vehicle-controlled, Dose-escalation, Single-center Study of the Safety and Clinical Effect of Nexagon® in the Treatment of Participants With Diabetic Foot Ulcers
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Diabetic Foot Ulcer
- Sponsor
- OcuNexus Therapeutics, Inc.
- Enrollment
- 24
- Locations
- 1
- Primary Endpoint
- To evaluate the safety and clinical effect of Nexagon® administered topically to diabetic foot ulcers.
- Status
- Terminated
- Last Updated
- 15 years ago
Overview
Brief Summary
Diabetic foot ulcers are sores on the feet that occur in 15% of diabetic patients some time during their lifetime. Once an ulcer develops, the risk of lower-extremity amputation is increased 8-fold in people with diabetes. New treatments that improve the number of ulcers that heal and/or speed up healing are urgently needed. Initial studies with a new drug called Nexagon® (developed by CoDa Therapeutics, Inc.) support the concept that healing of diabetic foot ulcers can be improved with topical application of Nexagon®. Further research will be undertaken to assess the safety and activity of Nexagon® when applied to diabetic foot ulcers at various doses. A proposed randomized controlled trial will randomly allocate (e.g., by the toss of a coin) 24 people with diabetic foot ulcers to Nexagon® (one of three different doses) or vehicle (substance containing no medication) to be applied to their ulcer three times over four weeks. Participants will be followed over four weeks to monitor their response to the treatment, specifically with regards to the amount of healing that occurs.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male or female aged 18 and older
- •Female subjects must be a) post-menopausal, b) surgically sterilized, c) practicing abstinence, or d) using hormonal contraceptive, intra-uterine device, diaphragm with spermicide or condom with spermicide for the duration of the study
- •Diabetes mellitus (type I or II) with an HbA1c \< 10.0%
- •Diagnosis of neuropathic foot ulcer
- •Cutaneous, full thickness (University of Texas grade A1), below ankle surface ulcer between 0.5 and 5.0 cm2 post-debridement
- •A viable, granulating wound
- •Ulcer present for \> 4 weeks prior to study entry
- •An ankle brachial index between 0.70 and 1.3 measured during screening or within three months prior to the Day -14 visit
- •Signed informed consent form
Exclusion Criteria
- •Decrease or increase in the ulcer size by 30% or more during a14 day "run-in" period
- •Cannot tolerate the off-loading method or comply with standard-of-care
- •An ulcer which shows signs of clinical infection
- •The ulcer to be treated requires operative debridement.
- •An ulcer positive for β-hemolytic streptococcus upon culture.
- •Requirement for total contact casts
- •The ulcer has more than 50% slough, significant necrotic tissue, osteomyelitis, bone, tendon, or capsule exposure
- •Presence of an active systemic or local cancer or tumor of any kind (with the exception of non-melanoma skin cancer)
- •Congestive heart failure NYHA class II - IV
- •Coronary heart disease with STEMI, CABG, or PTCA within the last 6 months
Outcomes
Primary Outcomes
To evaluate the safety and clinical effect of Nexagon® administered topically to diabetic foot ulcers.
Secondary Outcomes
- To select the optimal dose(s) which can be used in future trials of Nexagon® in diabetic foot ulcers
- To pilot the collection of data that may be considered useful in planning future studies of Nexagon® administered topically to diabetic foot ulcers.